Previse

Previse, formerly known as Capsulomics, is a genetic testing company that specializes in developing precision medicine solutions for the early detection and treatment of different types of cancer. The company developed its technology in the GI Early Detection Biomarker Lab at the Johns Hopkins University School of Medicine which was funded via a grant from the National Institute of Health.

In March 2023, the company launched its first laboratory-developed test, Esopredict , which allows gastroenterologists to offer a personalized approach to treating Barrett's esophagus, a precursor to esophagus cancer (EAC). The test provides a risk prediction report for the following five years called Esoscore to allow healthcare providers to determine a patient's likelihood of developing esophageal cancer and make informed decisions about their treatment, monitoring, and follow-up care. Furthermore, as of July 2023, the company was developing a minimally invasive sponge device to collect samples to test for EAC, which researchers believe is a better alternative to detecting EAC without endoscopy.

Funding and Financials

In March 2023, the company raised USD 3 million in a seed funding round. The new funds were used toward commercial activities and to create research demonstrating the practicality of the clinical application of Esopredict, which would serve as the foundation for securing insurance coverage and reimbursement for Esopredict.